Felzartamab
- Generic Name
- Felzartamab
- Drug Type
- Biotech
- CAS Number
- 2197112-39-1
- Unique Ingredient Identifier
- 3O9FA4XC02
- Background
Felzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 180
- Registration Number
- NCT06962800
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 454
- Registration Number
- NCT06935357
- Locations
- 🇺🇸
FOMAT Medical Research - FOMAT - PPDS, Oxnard, California, United States
🇺🇸Knoxville Kidney Center, PLLC, Knoxville, Tennessee, United States
🇺🇸R & H Clinical Research, Katy, Texas, United States
A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Biogen
- Target Recruit Count
- 120
- Registration Number
- NCT06685757
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- HI-Bio, A Biogen Company
- Target Recruit Count
- 20
- Registration Number
- NCT06064929
- Locations
- 🇺🇸
R & H Clinical Research, Katy, Texas, United States
🇺🇸Centricity Research - Phoenix, Mesa, Arizona, United States
🇺🇸University of California, San Diego (UCSD), La Jolla, California, United States
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
- Conditions
- Immunoglobulin A (IgA) Nephropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- HI-Bio, A Biogen Company
- Target Recruit Count
- 54
- Registration Number
- NCT05065970
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany
🇨🇿Fakultni nemocnice Kralovske Vinohrady Hospital, Prague, Praha, Hlavní Mesto, Czechia
🇬🇪JSC Evex Hospitals, Tbilisi, Georgia
Felzartamab in Late Antibody-Mediated Rejection
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Farsad Eskandary
- Target Recruit Count
- 22
- Registration Number
- NCT05021484
- Locations
- 🇩🇪
Charité University, Berlin, Germany
🇦🇹Medical University of Vienna, Vienna, Austria
MOR202 for Refractory MN
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Mario Negri Institute for Pharmacological Research
- Target Recruit Count
- 10
- Registration Number
- NCT04893096
- Locations
- 🇮🇹
ASST HPG23 - Unità di Nefrologia, Bergamo, BG, Italy
🇮🇹Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Ranica, BG, Italy
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)
- Conditions
- GlomerulonephritisantiPLA2R PositiveMembranous Nephropathy
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- HI-Bio, A Biogen Company
- Target Recruit Count
- 24
- Registration Number
- NCT04733040
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Kaohsiung, Taiwan
🇬🇪Managadze National Center of Urology, Tbilisi, Georgia
🇩🇪University Hospital Aachen, Aachen, Germany
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- HI-Bio, A Biogen Company
- Target Recruit Count
- 31
- Registration Number
- NCT04145440
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Northwest Louisiana Nephrology Research, Shreveport, Louisiana, United States
🇳🇱Radboud UMC Niimegen Nephrology, Nijmegen, Netherlands
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: MOR03087 phase 1 dose escalation
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 91
- Registration Number
- NCT01421186
- Locations
- 🇦🇹
AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I, Vienna, Austria
🇩🇪Medizinische Klinik II, Abt. Hämatologie, Onkologie,, Tübingen, Germany
🇩🇪Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie, Würzburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.